Benefits of immunotherapy combination persist for more than six years in advanced melanoma

(Dana-Farber Cancer Institute) In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment. The results, stemming from the CheckMate 067 clinical trial, represent a new landmark in survival rates for patients with melanoma treated with immune checkpoint inhibitor drugs.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news